Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 4 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Monopar Therapeutics changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 56 | 74 | +18 |
| Shares | 4.34M | 5.53M | +1.19M (+27.5%) |
| Value | $354.3M | $360.8M | +$6.50M (+1.8%) |
New holders (23)
Institutions that held Monopar Therapeutics at the end of Q4 2025 but not at the end of Q3 2025.
Sold out (5)
Institutions that held Monopar Therapeutics at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Affinity Asset Advisors, LLC | 79,483 | $6.49M |
| Ally Bridge Group (NY) LLC | 64,455 | $5.26M |
| Susquehanna International Group, LLP | 4,328 | $353.5K |
| State Board of Administration of Florida Retirement System | 3,508 | $286.5K |
| SRS Capital Advisors, Inc. | 14 | $1.14K |